HEPA earnings analysis
What we found in HEPA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q text contains no reported revenue, margins, EPS, cash flow, balance-sheet figures, segment results, or quantitative guidance, so operating trends cannot be assessed. The principal disclosure is that controls were ineffective as of June 30, 2026 because of 3 material weaknesses, including staffing and segregation-of-duties deficiencies, complex-accounting controls, and tax-provision controls. Management said it needs additional capital for remediation and could not assure timely remediation, creating a material execution and reporting risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remain ineffective
- As of June 30, 2026, management concluded that the company’s disclosure controls and procedures were not effective due to 3 identified material weaknesses in internal control over financial reporting.
- Additional capital needed for remediation
- Management stated that it needs to raise additional capital to add personnel and implement additional internal control procedures; no quantitative capital target was disclosed.
- Three remediation priorities identified
- The company listed 3 remediation areas involving personnel and segregation of duties, complex accounting transactions, and the income tax provision and related disclosures.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Broad internal-control deficiencies
- As of June 30, 2026, the control environment lacked a sufficient complement of personnel and proper segregation of duties, creating weaknesses across COSO components and business-process and IT general controls.
- Remediation timing and funding risk
- The company stated it cannot assure successful remediation of the material weaknesses in a timely manner, and remediation depends in part on raising additional capital.
- No formal risk-factor update
- The filing states there were no material changes to the risk factors disclosed in the Form 10-K for the year ended December 31, 2025; therefore, no new formal risk-factor changes were identified.
What they said about what is next.
The provided 10-Q text contains no quantitative revenue, EPS, or operating outlook. Outlook was not provided in the filing.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Hepion Pharmaceuticals reported no revenue for Q1 2026, consistent with the prior year. Operating expenses decreased substantially, resulting in a net loss which improved significantly compared to the prior year's loss.…
- 10-K · March 12, 2026
- Hepion Pharmaceuticals has pivoted from drug development to a diagnostics-focused strategy: it sold rencofilstat-related assets to Panetta (May 26, 2025) for a nominal amount and in‑licensed CE-marked diagnostic tests…
- 10-Q · November 14, 2024
- Hepion reported no revenue and a Q3 2024 net loss of $4,865,948 (EPS $(0.72)), an improvement versus Q3 2023 net loss of $10,526,946 (EPS $(2.74)) driven by sharply lower R&D and G&A spend. Cash fell to $1,497,106 at…
- 10-Q · August 13, 2024
- Hepion’s Q2 2024 shows sharply lower operating expenses and a much smaller net loss driven by expense cuts and non‑cash fair value gains, but liquidity is strained. Cash fell to $2.12M at June 30, 2024 and management…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing HEPA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever